Skip to content
Uptravi(selexipag)
Uptravi (selexipag) is a small molecule pharmaceutical. Selexipag was first approved as Uptravi on 2015-12-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target prostacyclin receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Uptravi (generic drugs available since 2022-12-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selexipag
Tradename
Company
Number
Date
Products
UPTRAVIActelionN-207947 RX2015-12-21
8 products, RLD
UPTRAVIActelionN-214275 RX2021-07-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
uptravi uptravi titration packNew Drug Application2021-11-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary hypertensionEFO_0001361D006976I27.20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Selexipag, Uptravi, Actelion
108211082036-12-01DPU-2992
108282982036-12-01DPU-2991
87911222030-08-01DS, DP
92842802030-06-25U-1831
91738812029-08-12U-1798
72053022026-10-31DS, DPU-1797
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC27: Selexipag
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD000081029—25119
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary hypertensionD006976EFO_0001361I27.20—23——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchistosomiasisD012552EFO_1001475B65—1———1
Systemic sclerodermaD012595EFO_0000717M34—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—7————7
Therapeutic equivalencyD0138101————1
PharmacokineticsD0105991————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thromboangiitis obliteransD013919EFO_1001211I73.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSELEXIPAG
INNselexipag
Description
Selexipag is a member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). It has a role as an orphan drug, a prostacyclin receptor agonist, a platelet aggregation inhibitor, a vasodilator agent and a prodrug. It is a monocarboxylic acid amide, an ether, a member of pyrazines, an aromatic amine, a tertiary amino compound and a N-sulfonylcarboxamide. It is functionally related to an ACT-333679.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1
Identifiers
PDB—
CAS-ID475086-01-2
RxCUI1729002
ChEMBL IDCHEMBL238804
ChEBI ID—
PubChem CID9913767
DrugBankDB11362
UNII ID5EXC0E384L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PTGIR
PTGIR
Organism
Homo sapiens
Gene name
PTGIR
Gene synonyms
PRIPR
NCBI Gene ID
5739
Protein name
prostacyclin receptor
Protein synonyms
PGI receptor, PGI2 receptor, prostaglandin I2 (prostacyclin) receptor (IP), Prostaglandin I2 receptor, Prostanoid IP receptor
Uniprot ID
P43119
Mouse ortholog
Ptgir (19222)
prostacyclin receptor (Q52KE5)
Variants
Clinical Variant
No data
Financial
Uptravi - Johnson & Johnson
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 784 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
97,358 adverse events reported
View more details